|
|
||||||||||||||
|
|
|||||||||||||||
ORIGINAL ARTICLE |
1 Institute of Pathology, University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany
2 Institute of Pathology, University of Tübingen, Tübingen, Germany
3 Department of Pathology, Mayo Clinic Jacksonville, Florida, USA
4 Department of Internal Medicine I, Division of Hematology, University of Vienna, Vienna, Austria
Correspondence to:
Professor H-P Horny, Institute of Pathology, University of Lübeck, Ratzeburger Allee 160, D-23538 Lübeck, Germany;
horny{at}patho.mu-luebeck.de
Background: Two cell specific neutral proteases, tryptase and chymase, are produced by human mast cells (MC). Tryptase is constitutively expressed by all MC, whereas chymase is found only in an MC subset. Very little is known about chymase expression in MC proliferative disorders (mastocytosis).
Aims and Methods: Routinely processed, formalin fixed, and paraffin wax embedded bone marrow trephine biopsy specimens obtained from patients with various subtypes of mastocytosis (n = 47) and myelodysplastic syndromes (MDS; n = 28) were immunostained with antibodies against chymase and tryptase. Normal/reactive bone marrow specimens with intact haemopoiesis (n = 31) served as controls. The numbers of chymase expressing (C+) and of tryptase expressing (T+) MC were assessed morphometrically using a computer assisted video camera system.
Results: In normal/reactive bone marrow, the numbers of C+ MC (median, 8/mm2; maximum, 159/mm2) were in the same range as those of T+ MC (median, 4/mm2; maximum, 167/mm2). Because normal MC express both chymase and tryptase, these findings indicate that the common phenotype of bone marrow MC in normal/reactive states is MCTC (MC expressing both tryptase and chymase). In contrast, in MDS and mastocytosis, the bone marrow exhibited far more T+ MC than C+ MC in almost all cases.
Conclusions: According to these findings, the predominant MC type in the bone marrow in neoplastic states such as MDS and mastocytosis is MCT (MC expressing only tryptase). Although the pathophysiological basis of this apparent lack of chymase expression in most neoplastic MC in mastocytosis and MC involved in MDS remains unknown, this study has produced further evidence of the superior value of antitryptase antibodies in the diagnosis of mastocytosis.
Keywords: bone marrow; chymase; mast cell; mastocytosis; tryptase
Abbreviations: C+, chymase expressing; MC, mast cells; MCC, mast cells expressing only chymase; MCT, mast cells expressing only tryptase; MCTC, mast cells expressing both tryptase and chymase; MDS, myelodysplastic syndromes; T+, tryptase expressing
This article has been cited by other articles:
![]() |
M.T. Krauth, M. Fodinger, L. Rebuzzi, R. Greul, A. Chott, and P. Valent Aggressive systemic mastocytosis with sarcoma-like growth in the skeleton, leukemic progression, and partial loss of mast cell differentiation antigens Haematologica, December 1, 2007; 92(12): e126 - e129. [Full Text] [PDF] |
||||
![]() |
O Ozdemir and S Savasan The role of mast cells in bone marrow diseases J. Clin. Pathol., January 1, 2004; 57(1): 108 - 109. [Full Text] |
||||
Read all eLetters
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS | REGISTER |
| Journal of Clinical Pathology | Molecular Pathology |